Risks and safety of pandemic h1n1 influenza vaccine in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants
•Information is needed on safety of pandemic H1N1 influenza vaccines in pregnancy.•1032 exposed pregnant women were followed to pregnancy outcome, 2009–2012.•No increases in birth defects, spontaneous abortion or growth restriction were seen.•Vaccinated women on average delivered 3 days earlier than...
Saved in:
| Published in | Vaccine Vol. 31; no. 44; pp. 5026 - 5032 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
17.10.2013
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | •Information is needed on safety of pandemic H1N1 influenza vaccines in pregnancy.•1032 exposed pregnant women were followed to pregnancy outcome, 2009–2012.•No increases in birth defects, spontaneous abortion or growth restriction were seen.•Vaccinated women on average delivered 3 days earlier than non-vaccinated.•This study adds to the reassuring literature about pH1N1 vaccines in pregnancy.
There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy.
To assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure.
There were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26–2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31–2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25–8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0.
For the 2009–12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days. |
|---|---|
| AbstractList | •Information is needed on safety of pandemic H1N1 influenza vaccines in pregnancy.•1032 exposed pregnant women were followed to pregnancy outcome, 2009–2012.•No increases in birth defects, spontaneous abortion or growth restriction were seen.•Vaccinated women on average delivered 3 days earlier than non-vaccinated.•This study adds to the reassuring literature about pH1N1 vaccines in pregnancy.
There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy.
To assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure.
There were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26–2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31–2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25–8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0.
For the 2009–12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days. There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy.INTRODUCTIONThere is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy.To assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure.METHODSTo assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure.There were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26-2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31-2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25-8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0.RESULTSThere were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26-2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31-2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25-8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0.For the 2009-12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days.CONCLUSIONSFor the 2009-12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days. There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy. To assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure. There were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26-2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31-2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25-8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0. For the 2009-12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days. Highlights•Information is needed on safety of pandemic H1N1 influenza vaccines in pregnancy. •1032 exposed pregnant women were followed to pregnancy outcome, 2009–2012. •No increases in birth defects, spontaneous abortion or growth restriction were seen. •Vaccinated women on average delivered 3 days earlier than non-vaccinated. •This study adds to the reassuring literature about pH1N1 vaccines in pregnancy. Introduction There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy. Methods To assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure. Results There were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26-2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31-2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25-8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0. Conclusions For the 2009-12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days. There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing vaccines in women exposed during pregnancy.To assess risks and relative safety of the pH1N1-containing vaccines, we conducted a prospective cohort study of pH1N1-vaccine-exposed and unexposed comparison women residing in the U.S. or Canada who were recruited during pregnancy and followed to outcome between October 2009 and August 2012. For exposure to the pH1N1 vaccine, adjusted relative risks (RRs) and 95% confidence intervals (CIs) were estimated for major birth defects and infants small for gestational age. Adjusted hazard ratios (HRs) and 95% CIs were estimated for spontaneous abortion and preterm delivery for time-varying exposure.There were 1032 subjects available for analysis; 841 women were exposed to a pH1N1-containing vaccine in pregnancy, and 191 women were unexposed to any influenza vaccine in pregnancy. Nine of 328 (2.7%) first-trimester-exposed pregnancies resulted in an infant with a major birth defect compared to 6/188 (3.2%) in the unexposed (adjusted RR 0.79, 95% CI 0.26–2.42). The HR for spontaneous abortion was not elevated (adjusted HR 0.92, 95% CI 0.31–2.72). Adjusted HRs for preterm delivery were elevated for exposure anytime in pregnancy (3.28, 95% CI 1.25–8.63), specifically with exposure in the 1st or 2nd trimester. However, the mean decrease in gestational age in the exposed pregnancies was approximately three days. Adjusted RRs for small for gestational age infants on weight and length approximated 1.0.For the 2009–12 influenza seasons combined, we found no meaningful evidence of increased RR or HR for major birth defects, spontaneous abortion, or small for gestational age infants. There was some evidence of an increased HR for preterm delivery following pH1N1-influenza vaccine exposure; however the decrease in gestational age on average was approximately three days. |
| Author | Johnson, Diana Jones, Kenneth L. Chambers, Christina D. Louik, Carol Schatz, Michael Xu, Ronghui Luo, Yunjun Mitchell, Allen A. |
| Author_xml | – sequence: 1 givenname: Christina D. surname: Chambers fullname: Chambers, Christina D. email: chchambers@ucsd.edu organization: Department of Pediatrics, University of California San Diego, La Jolla, CA, United States – sequence: 2 givenname: Diana surname: Johnson fullname: Johnson, Diana organization: Department of Pediatrics, University of California San Diego, La Jolla, CA, United States – sequence: 3 givenname: Ronghui surname: Xu fullname: Xu, Ronghui organization: Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, United States – sequence: 4 givenname: Yunjun surname: Luo fullname: Luo, Yunjun organization: Department of Pediatrics, University of California San Diego, La Jolla, CA, United States – sequence: 5 givenname: Carol surname: Louik fullname: Louik, Carol organization: Slone Epidemiology Center at Boston University, Boston, MA, United States – sequence: 6 givenname: Allen A. surname: Mitchell fullname: Mitchell, Allen A. organization: Slone Epidemiology Center at Boston University, Boston, MA, United States – sequence: 7 givenname: Michael surname: Schatz fullname: Schatz, Michael organization: American Academy of Allergy Asthma and Immunology, Milwaukee, WI, United States – sequence: 8 givenname: Kenneth L. surname: Jones fullname: Jones, Kenneth L. organization: Department of Pediatrics, University of California San Diego, La Jolla, CA, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27953839$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24016809$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk12LEzEUhoOsuN3Vn6AERPCirclkkskoKrr4BQuCH-BdSDMn3XRnMjWZFuqP8beaMF0WCtK9GjI85z0n531zhk587wGhx5TMKaHixWq-1cY4D_OCUDYnck7q6h6aUFmxWcGpPEETUohyVlLy6xSdxbgihHBG6wfotCiThCT1BP395uJ1xNo3OGoLww73Fq_TETpn8BX1FDtv2w34PxrvO6Y_eB1g6bU3u5f4vQvDFW7AghniFMd17wftod8k2UUfBtf7aeYHCF3CWreFsJuOLTvdttj2AS8hDjqjusV6mVtY7Yf4EN23uo3waP89Rz8_fvhx8Xl2-fXTl4t3lzMj6mqYmWYBaXqhzaKxhbEgCSXG2ppBo40QDWEVJYKXtSC0MrxuaAWlNlZSsyipZufo-ai7Dv3vTZpFdS4aaNvxIiptS1SUEcaOo5yKiouay-NoKUpOuOTVHdCSlZSXMqNPD9BVvwlpcbk3lzIxNFNP9tRm0UGj1sF1OuzUjfUJeLYHdDS6tSG56eItV9WcSZa5VyNnQh9jAKuMG60agnatokTlQKqV2sdD5UAqIlUKZKrmB9U3DY7VvR3rILm-dRBUNA68gcaFlDPV9O6owpsDBdM679JVr2EH8XZnKhaKqO_5seS3klymxSjw-v8CdxjgH63IJ9o |
| CODEN | VACCDE |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2017_08_080 crossref_primary_10_1542_peds_2021_053745 crossref_primary_10_1080_21645515_2015_1059976 crossref_primary_10_1097_AOG_0000000000000593 crossref_primary_10_1097_AOG_0000000000002573 crossref_primary_10_1111_aogs_12680 crossref_primary_10_1016_j_vaccine_2024_126256 crossref_primary_10_15585_mmwr_rr7005a1 crossref_primary_10_12968_bjom_2020_28_2_78 crossref_primary_10_1002_bdr2_23622 crossref_primary_10_1016_j_vaccine_2015_08_043 crossref_primary_10_1002_pds_3784 crossref_primary_10_1016_j_vaccine_2016_06_078 crossref_primary_10_1016_j_vaccine_2017_01_040 crossref_primary_10_1093_cid_ciy517 crossref_primary_10_1016_S1473_3099_17_30190_1 crossref_primary_10_1177_1933719114537720 crossref_primary_10_1080_21645515_2016_1186312 crossref_primary_10_1093_cid_ciu915 crossref_primary_10_15585_mmwr_rr6803a1 crossref_primary_10_1002_bdr2_1852 crossref_primary_10_1097_AOG_0000000000005279 crossref_primary_10_1093_aje_kww043 crossref_primary_10_15585_mmwr_rr7101a1 crossref_primary_10_1016_j_vaccine_2015_11_020 crossref_primary_10_1542_peds_2022_059275 crossref_primary_10_1016_j_jiac_2015_01_015 crossref_primary_10_1111_1471_0528_12977 crossref_primary_10_14789_jmj_60_s42 crossref_primary_10_3810_hp_2014_04_1109 crossref_primary_10_1080_21645515_2018_1540807 crossref_primary_10_1080_14760584_2016_1175304 crossref_primary_10_15585_mmwr_rr6703a1 crossref_primary_10_1177_003335491513000104 crossref_primary_10_1016_j_vaccine_2017_04_074 crossref_primary_10_1016_j_siny_2013_11_014 crossref_primary_10_1016_j_vaccine_2022_04_076 crossref_primary_10_1007_s40475_019_00188_9 crossref_primary_10_1517_14728222_2014_855201 crossref_primary_10_1016_j_vaccine_2017_06_069 crossref_primary_10_1080_14767058_2019_1680633 crossref_primary_10_3390_ijerph110303074 crossref_primary_10_1016_j_vaccine_2016_06_054 crossref_primary_10_1111_ppe_12715 crossref_primary_10_7326_M21_3668 crossref_primary_10_1016_j_vaccine_2021_09_003 crossref_primary_10_1080_14760584_2018_1471988 crossref_primary_10_1136_bmjopen_2022_066182 crossref_primary_10_15585_mmwr_mm6439a3 crossref_primary_10_15585_mmwr_rr7305a1 crossref_primary_10_1097_AOG_0000000000001068 crossref_primary_10_1016_j_vaccine_2015_03_041 crossref_primary_10_1016_j_vaccine_2021_09_043 crossref_primary_10_1016_j_vaccine_2014_07_017 crossref_primary_10_1016_j_vaccine_2016_03_047 crossref_primary_10_1111_ppe_12595 crossref_primary_10_15585_mmwr_rr6908a1 crossref_primary_10_1016_j_vaccine_2020_01_059 crossref_primary_10_1016_j_wombi_2020_01_009 crossref_primary_10_1111_ppe_12152 crossref_primary_10_3389_fimmu_2020_01282 crossref_primary_10_1002_ijgo_12394 crossref_primary_10_1542_peds_2023_063773 crossref_primary_10_1542_peds_2024_068508 crossref_primary_10_1186_s13643_016_0347_9 crossref_primary_10_1002_bdra_23622 crossref_primary_10_1016_j_ijid_2020_01_033 crossref_primary_10_1016_j_pmedr_2015_04_011 crossref_primary_10_1016_j_vaccine_2014_09_054 crossref_primary_10_1016_j_vaccine_2019_09_035 crossref_primary_10_2196_10347 crossref_primary_10_1002_pds_5177 crossref_primary_10_1186_s12889_021_10740_w crossref_primary_10_1038_s41541_024_00889_x crossref_primary_10_1002_pds_3754 crossref_primary_10_1002_14651858_CD001269_pub6 crossref_primary_10_15585_mmwr_rr7202a1 crossref_primary_10_1016_j_jri_2021_103464 crossref_primary_10_3346_jkms_2016_31_7_1063 |
| Cites_doi | 10.1016/S1701-2163(16)35336-1 10.1371/journal.pone.0051734 10.1056/NEJMoa1207210 10.1111/j.1471-0528.2012.03470.x 10.1016/j.ajog.2011.12.027 10.1542/peds.37.3.403 10.1016/j.vaccine.2012.10.112 10.1093/cid/cit045 10.1371/journal.pone.0023049 10.2105/AJPH.2011.300606 10.1016/j.vaccine.2011.04.114 10.1002/tera.1071 10.1016/j.ajog.2011.02.041 10.1016/j.vaccine.2012.04.081 10.1371/journal.pone.0052303 10.1016/j.vaccine.2012.10.064 10.1016/j.vaccine.2011.02.097 10.1016/j.vaccine.2013.04.031 10.1503/cmaj.110754 10.1371/journal.pmed.1000441 10.1097/AOG.0b013e3181fae845 10.1007/s10995-012-0957-3 10.1093/aje/kwj149 10.1136/bmj.e2794 10.1016/j.vaccine.2011.10.034 10.1016/j.ajog.2012.07.002 10.1016/j.ajog.2011.01.047 10.1542/peds.32.5.793 10.1007/s40264-013-0030-1 10.1016/j.vaccine.2013.08.096 10.1001/jama.2012.6131 10.1016/j.jaci.2005.05.027 |
| ContentType | Journal Article |
| Contributor | Conover, E Soldin, O P Briggs, G Riordan, S Djokanovic, N Debus, B Pupco, A Koren, G Quinn, D Roth, M Feingold, M Wolfe, L Carey, J Robertson, J Miller, R Berard, A Bakhireva, L Brochu, J Kao, K Lamm, S Cole, P Lavigne, S Polifka, J Wisner, K |
| Contributor_xml | – sequence: 1 givenname: D surname: Quinn fullname: Quinn, D – sequence: 2 givenname: S surname: Riordan fullname: Riordan, S – sequence: 3 givenname: K surname: Kao fullname: Kao, K – sequence: 4 givenname: J surname: Brochu fullname: Brochu, J – sequence: 5 givenname: S surname: Lavigne fullname: Lavigne, S – sequence: 6 givenname: E surname: Conover fullname: Conover, E – sequence: 7 givenname: P surname: Cole fullname: Cole, P – sequence: 8 givenname: M surname: Feingold fullname: Feingold, M – sequence: 9 givenname: M surname: Roth fullname: Roth, M – sequence: 10 givenname: R surname: Miller fullname: Miller, R – sequence: 11 givenname: B surname: Debus fullname: Debus, B – sequence: 12 givenname: L surname: Wolfe fullname: Wolfe, L – sequence: 13 givenname: J surname: Carey fullname: Carey, J – sequence: 14 givenname: J surname: Robertson fullname: Robertson, J – sequence: 15 givenname: N surname: Djokanovic fullname: Djokanovic, N – sequence: 16 givenname: A surname: Pupco fullname: Pupco, A – sequence: 17 givenname: G surname: Koren fullname: Koren, G – sequence: 18 givenname: G surname: Briggs fullname: Briggs, G – sequence: 19 givenname: J surname: Polifka fullname: Polifka, J – sequence: 20 givenname: S surname: Lamm fullname: Lamm, S – sequence: 21 givenname: O P surname: Soldin fullname: Soldin, O P – sequence: 22 givenname: A surname: Berard fullname: Berard, A – sequence: 23 givenname: K surname: Wisner fullname: Wisner, K – sequence: 24 givenname: L surname: Bakhireva fullname: Bakhireva, L |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Oct 17, 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Oct 17, 2013 |
| CorporateAuthor | the OTIS Collaborative Research Group OTIS Collaborative Research Group |
| CorporateAuthor_xml | – name: the OTIS Collaborative Research Group – name: OTIS Collaborative Research Group |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7U1 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2013.08.097 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic Risk Abstracts AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic Risk Abstracts AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Research Library Prep Risk Abstracts AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central (New) url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 5032 |
| ExternalDocumentID | 3419663231 24016809 27953839 10_1016_j_vaccine_2013_08_097 S0264410X13012097 1_s2_0_S0264410X13012097 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GeographicLocations | Canada United States United States--US |
| GeographicLocations_xml | – name: Canada – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Department of Health and Human Services grantid: HHS0100201000029C – fundername: OTIS Collaborative Research Group – fundername: PHS HHS grantid: HHS0100201000029C |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG LCYCR QYZTP AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7U1 7S9 L.6 |
| ID | FETCH-LOGICAL-c697t-cdbeafe6acbdf2cfe8010cff93edac66d0371065496017c59d17e4acf81cb41a3 |
| IEDL.DBID | .~1 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Fri Jul 11 05:52:45 EDT 2025 Fri Jul 11 11:50:11 EDT 2025 Thu Jul 10 18:39:11 EDT 2025 Tue Aug 05 11:25:15 EDT 2025 Wed Aug 13 09:25:37 EDT 2025 Thu Apr 03 07:00:27 EDT 2025 Wed Apr 02 07:26:33 EDT 2025 Tue Jul 01 03:38:05 EDT 2025 Thu Apr 24 22:59:52 EDT 2025 Fri Feb 23 02:26:54 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Aug 26 16:33:24 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 44 |
| Keywords | Pregnancy Birth defects Pandemic H1N1 influenza vaccination Small for gestational age Spontaneous abortion Preterm delivery Human Intrauterine growth retardation Pregnancy disorders Vaccination Premature delivery Orthomyxoviridae Infant Vaccine Abortion Virus Fetal diseases Influenzavirus A Prematurity Influenza A virus |
| Language | English |
| License | CC BY 4.0 Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c697t-cdbeafe6acbdf2cfe8010cff93edac66d0371065496017c59d17e4acf81cb41a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 24016809 |
| PQID | 1558848717 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1686713033 proquest_miscellaneous_1516756958 proquest_miscellaneous_1464505857 proquest_miscellaneous_1443415487 proquest_journals_1558848717 pubmed_primary_24016809 pascalfrancis_primary_27953839 crossref_citationtrail_10_1016_j_vaccine_2013_08_097 crossref_primary_10_1016_j_vaccine_2013_08_097 elsevier_sciencedirect_doi_10_1016_j_vaccine_2013_08_097 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X13012097 elsevier_clinicalkey_doi_10_1016_j_vaccine_2013_08_097 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-10-17 |
| PublicationDateYYYYMMDD | 2013-10-17 |
| PublicationDate_xml | – month: 10 year: 2013 text: 2013-10-17 day: 17 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Netherlands |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Richards, Hansen, Bredfeldt, Bednarczyk, Steinhoff, Adjaye-Gbewonyo (bib0150) 2013; 56 Schatz, Chambers, Jones, Louik, Mitchell (bib0175) 2011; 204 (bib0070) 2009; 58 (bib0030) 2010; 116 Huang, Chen, Teng, Huang, Huang, Hsu (bib0095) 2011; 6 Kallen, Olausson (bib0165) 2012; 119 Hollingshead (bib0235) 1975 Bednarczyk, Adjaye-Gbewonyo, Omer (bib0020) 2012 Omer, Goodman, Steinhoff, Rochat, Klugman, Stoll (bib0080) 2011; 8 Omon, Damase-Michel, Hurault-Delarue, Lacroix, Monstastruc, Oustric (bib0140) 2011; 29 Correa, Cragan, Kucik, Alverson, Gilboa, Balakrishnan (bib0205) 2007; 79 Eppes, Wu, You, Cameron, Garcia, Grobman (bib0065) 2013; 31 Louik, Chambers, Jacobs, Rice, Johnson, Mitchell (bib0200) 2013; 22 (bib0035) 2012; 61 Louik, Ahrens, Kerr, Pyo, Chambers, Jones (bib0180) 2013 Tamma, Ault, del Rio, Steinhoff, Halsey, Omer (bib0015) 2011; 204 Dlugacz, Fleischer, Carney, Copperman, Ahmed, Ross (bib0050) 2012; 206 Sammon, Snowball, McGrogan, de Vries (bib0155) 2012; 7 Brookhart, Schneeweiss, Rothman, Glynn, Avorn, Sturmer (bib0230) 2006; 163 Pasternak, Svanstrom, Molgaard-Nielsen, Krause, Emborg, Melbye (bib0120) 2012; 308 Chavant, Ingrand, Jonville-Bera, Plazanet, Gras-Champel, Lagarce (bib0170) 2013; 36 Xu, Luo, Chambers (bib0225) 2012; 21 Lubchenco, Hansmann, Dressler, Boyd (bib0215) 1963; 32 Lubchenco, Hansmann, Boyd (bib0220) 1966; 37 Fisher, Scott, Hart, Winn, Gibbs, Lynch (bib0040) 2011; 204 Steinhoff, Omer, Roy, El Arifeen, Raqib, Dodd (bib0085) 2012; 184 Fell, Sprague, Liu, Yasseen, Wen, Smith (bib0110) 2012; 102 Gorman, Brewer, Wang, Chambers (bib0060) 2012; 31 Parretta, Ianniello, Ferrazin, Rossi, Capuano (bib0100) 2011; 9 Chambers, Braddock, Briggs, Einarson, Johnson, Miller (bib0185) 2001; 64 Kelley, Kelley, Kaufman, Mitchell (bib0195) 2003; 12 U.S. National Center for Health Statistics 2000 growth charts. Accessed 15 November 2012 at Pasternak, Molgaard-Nielsen Svanstrom, Krause, Emborg, Melbye, Hviid (bib0115) 2012; 344 Launay, Krivine, Charlier, Truster, Tsatsaris, Lepercq (bib0145) 2012; 7 Heikkinen, Young, van Beek, Franke, Verstraeten, Weil (bib0130) 2012; 177 Meharry, Colson, Grizas, Stiller, Vazquez (bib0045) 2012; 17 . Moro, Broder, Zheteyeva, Walton, Rohan, Sutherland (bib0075) 2011; 146 Lin, Lin, Lin, Lin, Lin, Chiu (bib0135) 2012; l30 Tavares, Nazareth, Monegal, Kolte, Verstraeten, Vauchau (bib0105) 2011; 29 Dodds, Macdonald, Scott, Spencer, Allen, McNeil (bib0090) 2012; 34 (bib0010) 2011; 60 Rasmussen, Jamieson, Uyeki (bib0005) 2011; 204 Harper, Fukuda, Uyeki, Cox, Bridges (bib0025) 2005; 54 Drees, Tambourelli, Denstman, Zhang, Zent, McGraw (bib0055) 2012; 31 Oppermann, Fritzsche, Weber-Schoendorfer, Keller-Stanislawski, Allignol, Meister (bib0125) 2012; 30 Bakhireva, Jones, Schatz, Johnson, Chambers (bib0190) 2005; 116 Haberg, Trogstad, Gunnes, Wilcox, Gjessing, Samuelsen (bib0160) 2013; 368 Haberg (10.1016/j.vaccine.2013.08.097_bib0160) 2013; 368 (10.1016/j.vaccine.2013.08.097_bib0030) 2010; 116 Steinhoff (10.1016/j.vaccine.2013.08.097_bib0085) 2012; 184 Harper (10.1016/j.vaccine.2013.08.097_bib0025) 2005; 54 Fell (10.1016/j.vaccine.2013.08.097_bib0110) 2012; 102 Chambers (10.1016/j.vaccine.2013.08.097_bib0185) 2001; 64 Gorman (10.1016/j.vaccine.2013.08.097_bib0060) 2012; 31 Lin (10.1016/j.vaccine.2013.08.097_bib0135) 2012; l30 (10.1016/j.vaccine.2013.08.097_bib0070) 2009; 58 10.1016/j.vaccine.2013.08.097_bib0210 Richards (10.1016/j.vaccine.2013.08.097_bib0150) 2013; 56 Sammon (10.1016/j.vaccine.2013.08.097_bib0155) 2012; 7 Kallen (10.1016/j.vaccine.2013.08.097_bib0165) 2012; 119 Oppermann (10.1016/j.vaccine.2013.08.097_bib0125) 2012; 30 Fisher (10.1016/j.vaccine.2013.08.097_bib0040) 2011; 204 Lubchenco (10.1016/j.vaccine.2013.08.097_bib0220) 1966; 37 (10.1016/j.vaccine.2013.08.097_bib0035) 2012; 61 Louik (10.1016/j.vaccine.2013.08.097_bib0200) 2013; 22 Louik (10.1016/j.vaccine.2013.08.097_bib0180) 2013 Huang (10.1016/j.vaccine.2013.08.097_bib0095) 2011; 6 Meharry (10.1016/j.vaccine.2013.08.097_bib0045) 2012; 17 Lubchenco (10.1016/j.vaccine.2013.08.097_bib0215) 1963; 32 Omon (10.1016/j.vaccine.2013.08.097_bib0140) 2011; 29 Tavares (10.1016/j.vaccine.2013.08.097_bib0105) 2011; 29 Hollingshead (10.1016/j.vaccine.2013.08.097_bib0235) 1975 Correa (10.1016/j.vaccine.2013.08.097_bib0205) 2007; 79 Parretta (10.1016/j.vaccine.2013.08.097_bib0100) 2011; 9 Omer (10.1016/j.vaccine.2013.08.097_bib0080) 2011; 8 Launay (10.1016/j.vaccine.2013.08.097_bib0145) 2012; 7 Kelley (10.1016/j.vaccine.2013.08.097_bib0195) 2003; 12 Chavant (10.1016/j.vaccine.2013.08.097_bib0170) 2013; 36 Pasternak (10.1016/j.vaccine.2013.08.097_bib0115) 2012; 344 Drees (10.1016/j.vaccine.2013.08.097_bib0055) 2012; 31 Xu (10.1016/j.vaccine.2013.08.097_bib0225) 2012; 21 Rasmussen (10.1016/j.vaccine.2013.08.097_bib0005) 2011; 204 Moro (10.1016/j.vaccine.2013.08.097_bib0075) 2011; 146 Bednarczyk (10.1016/j.vaccine.2013.08.097_bib0020) 2012 Eppes (10.1016/j.vaccine.2013.08.097_bib0065) 2013; 31 Pasternak (10.1016/j.vaccine.2013.08.097_bib0120) 2012; 308 (10.1016/j.vaccine.2013.08.097_bib0010) 2011; 60 Tamma (10.1016/j.vaccine.2013.08.097_bib0015) 2011; 204 Dodds (10.1016/j.vaccine.2013.08.097_bib0090) 2012; 34 Schatz (10.1016/j.vaccine.2013.08.097_bib0175) 2011; 204 Dlugacz (10.1016/j.vaccine.2013.08.097_bib0050) 2012; 206 Bakhireva (10.1016/j.vaccine.2013.08.097_bib0190) 2005; 116 Heikkinen (10.1016/j.vaccine.2013.08.097_bib0130) 2012; 177 Brookhart (10.1016/j.vaccine.2013.08.097_bib0230) 2006; 163 |
| References_xml | – volume: 31 start-page: 362 year: 2012 end-page: 366 ident: bib0055 article-title: Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010-11 influenza season publication-title: Vaccine – volume: 58 start-page: 1 year: 2009 end-page: 8 ident: bib0070 article-title: Use of influenza A (H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 publication-title: MMWR Morb Mortal Wkly Rep – volume: 204 start-page: S3 year: 2011 end-page: S8 ident: bib0005 article-title: Effects of influenza on pregnant women and infants publication-title: Am J Obstet Gynecol – volume: l30 start-page: 267 year: 2012 end-page: 275 ident: bib0135 article-title: AdimFlu-S influenza A (H1N1) vaccine during pregnancy the Taiwanese Pharmacovigilance Survey publication-title: Vaccine – volume: 64 start-page: 252 year: 2001 end-page: 261 ident: bib0185 article-title: Postmarketing surveillance for human teratogenicity: a model approach publication-title: Teratology – volume: 21 start-page: 844 year: 2012 end-page: 850 ident: bib0225 article-title: Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models publication-title: Drug Saf – volume: 34 start-page: 714 year: 2012 end-page: 720 ident: bib0090 article-title: The association between influenza vaccine in pregnancy and adverse neonatal outcomes publication-title: J Obstet Gynaecol Can – volume: 119 start-page: 1583 year: 2012 end-page: 1590 ident: bib0165 article-title: Vaccination against H1N1 influenza with Pandemrix publication-title: BJOG – volume: 308 start-page: 165 year: 2012 end-page: 180 ident: bib0120 article-title: Risk of adverse fetal outcomes following administration of a pandemic influenza A (H1N1) vaccine during pregnancy publication-title: JAMA – start-page: S38 year: 2012 end-page: S46 ident: bib0020 article-title: Safety of influenza immunization during pregnancy for the fetus and the neonate publication-title: Am J Obstet Gyn – volume: 163 start-page: 1149 year: 2006 end-page: 1156 ident: bib0230 article-title: Variable selection for propensity score models publication-title: Am J Epidemiol – volume: 79 start-page: 65 year: 2007 end-page: 186 ident: bib0205 article-title: Reporting birth defects surveillance data 1968–2003 publication-title: Birth Defects Res A Clin Mol Teratol – volume: 6 start-page: e23049 year: 2011 ident: bib0095 article-title: Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women-Taiwan, November 2009–August 2010 publication-title: PLoS One – volume: 7 start-page: e51734 year: 2012 ident: bib0155 article-title: Evaluating the hazard of foetal death following H1N1 influenza vaccination; A population based cohort study in the UK GPRD publication-title: PLoS One – volume: 206 start-page: e1 year: 2012 end-page: e8 ident: bib0050 article-title: 2009 H1N1 vaccination by pregnant women during the 2009–10 H1N1 influenza pandemic publication-title: Am J Obstet Gynecol – year: 2013 ident: bib0180 article-title: Risks and safety of H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects publication-title: Vaccine – volume: 17 start-page: 156 year: 2012 end-page: 164 ident: bib0045 article-title: Reasons why women accept or reject the trivalent inactivated influenza vaccine (TIV) during pregnancy publication-title: Matern Child Health J – volume: 32 start-page: 793 year: 1963 end-page: 800 ident: bib0215 article-title: Intrauterine growth as estimated from liveborn birthweight data at 24 to 42 weeks of gestaton publication-title: Pediatrics – volume: 12 start-page: S168 year: 2003 end-page: S198 ident: bib0195 article-title: The Slone Drug Dictionary: a research driven pharmacoepidemiology tool publication-title: Pharmacoepidemiol Drug Saf – volume: 22 start-page: 33 year: 2013 end-page: 39 ident: bib0200 article-title: Influenza vaccine safety in pregnancy: can we identify exposures publication-title: Drug Saf – volume: 204 start-page: S107 year: 2011 end-page: S111 ident: bib0040 article-title: Behaviors and perceptions regarding seasonal and H1N1 influenza vaccination during pregnancy publication-title: Am J Obstet Gynecol – volume: 29 start-page: 6358 year: 2011 end-page: 6365 ident: bib0105 article-title: Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study publication-title: Vaccine – volume: 184 start-page: 645 year: 2012 end-page: 653 ident: bib0085 article-title: Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial publication-title: CMAJ – volume: 116 start-page: 503 year: 2005 end-page: 509 ident: bib0190 article-title: Organization of Teratology Information Services Research Group. Asthma medication use in pregnancy and fetal growth publication-title: J Allergy Clin Immunol – volume: 56 start-page: 1216 year: 2013 end-page: 1222 ident: bib0150 article-title: Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age publication-title: Clin Infect Dis – volume: 60 start-page: 1193 year: 2011 end-page: 1196 ident: bib0010 article-title: Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)-United States, April 2009–August 2010 publication-title: MMWR Morb Mortal Wkly Rep – volume: 31 start-page: 213 year: 2012 end-page: 218 ident: bib0060 article-title: Theory-based predictors of influenza vaccination among pregnant women publication-title: Vaccine – volume: 61 start-page: 113 year: 2012 end-page: 118 ident: bib0035 article-title: Influenza vaccination coverage among pregnant women-29 states and New York City, 2009–10 season publication-title: MMWR Morb Mortal Wkly Rep – volume: 368 start-page: 333 year: 2013 end-page: 340 ident: bib0160 article-title: Risk of fetal death after pandemic influenza infection or vaccination during pregnancy publication-title: N Engl J Med – year: 1975 ident: bib0235 article-title: Four Factor Index of Social Status. Unpublished working paper – volume: 36 start-page: 455 year: 2013 end-page: 465 ident: bib0170 article-title: The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza publication-title: Drug Saf – volume: 204 start-page: S64 year: 2011 end-page: S68 ident: bib0175 article-title: Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System publication-title: Am J Obstet Gynecol – volume: 54 start-page: 1 year: 2005 end-page: 40 ident: bib0025 article-title: Prevention and control of influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm Rep – volume: 7 start-page: e52303 year: 2012 ident: bib0145 article-title: Low rate of pandemic A/H1N1 2009 influenza infection and lack of severe complication of vaccination in pregnant women: a prospective cohort study publication-title: PLoS One – volume: 204 start-page: S47 year: 2011 end-page: S52 ident: bib0015 article-title: Safety of influenza vaccination during pregnancy publication-title: Am J Obstet Gynecol – volume: 116 start-page: 1006 year: 2010 end-page: 1007 ident: bib0030 article-title: ACOG Committee Opinion No. 468: influenza vaccination during pregnancy publication-title: Obstet Gynecol – reference: . – volume: 8 start-page: e1000441 year: 2011 ident: bib0080 article-title: Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retorspective cohort study publication-title: PLoS Med. – volume: 31 start-page: 2874 year: 2013 end-page: 2878 ident: bib0065 article-title: Barriers to influenza vaccination among pregnant women publication-title: Vaccine – volume: 146 start-page: e1 year: 2011 end-page: e7 ident: bib0075 article-title: Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990–2009 publication-title: Am J Obstet Gynecol – volume: 177 start-page: e1 year: 2012 end-page: e8 ident: bib0130 article-title: Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study publication-title: Am J Obstet Gynecol – volume: 37 start-page: 403 year: 1966 end-page: 407 ident: bib0220 article-title: Intrauterine growth in length and head circumference as estimated from libirth at gestational ages from 26 to 42 weeks publication-title: Pediatrics – reference: U.S. National Center for Health Statistics 2000 growth charts. Accessed 15 November 2012 at: – volume: 29 start-page: 9649 year: 2011 end-page: 9654 ident: bib0140 article-title: Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study publication-title: Vaccine – volume: 9 start-page: 3708 year: 2011 end-page: 3713 ident: bib0100 article-title: Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination publication-title: Vaccine – volume: 102 start-page: e33 year: 2012 end-page: e40 ident: bib0110 article-title: H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes publication-title: Am J Public Health – volume: 30 start-page: 4445 year: 2012 end-page: 4452 ident: bib0125 article-title: A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy publication-title: Vaccine – volume: 344 start-page: e2794 year: 2012 ident: bib0115 article-title: Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark publication-title: BMJ – volume: 60 start-page: 1193 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0010 article-title: Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)-United States, April 2009–August 2010 publication-title: MMWR Morb Mortal Wkly Rep – volume: 34 start-page: 714 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0090 article-title: The association between influenza vaccine in pregnancy and adverse neonatal outcomes publication-title: J Obstet Gynaecol Can doi: 10.1016/S1701-2163(16)35336-1 – volume: 177 start-page: e1 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0130 article-title: Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study publication-title: Am J Obstet Gynecol – volume: 7 start-page: e51734 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0155 article-title: Evaluating the hazard of foetal death following H1N1 influenza vaccination; A population based cohort study in the UK GPRD publication-title: PLoS One doi: 10.1371/journal.pone.0051734 – volume: 368 start-page: 333 year: 2013 ident: 10.1016/j.vaccine.2013.08.097_bib0160 article-title: Risk of fetal death after pandemic influenza infection or vaccination during pregnancy publication-title: N Engl J Med doi: 10.1056/NEJMoa1207210 – volume: 119 start-page: 1583 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0165 article-title: Vaccination against H1N1 influenza with Pandemrix® during pregnancy and delivery outcome: a Swedish register study publication-title: BJOG doi: 10.1111/j.1471-0528.2012.03470.x – volume: 206 start-page: e1 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0050 article-title: 2009 H1N1 vaccination by pregnant women during the 2009–10 H1N1 influenza pandemic publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2011.12.027 – volume: 37 start-page: 403 year: 1966 ident: 10.1016/j.vaccine.2013.08.097_bib0220 article-title: Intrauterine growth in length and head circumference as estimated from libirth at gestational ages from 26 to 42 weeks publication-title: Pediatrics doi: 10.1542/peds.37.3.403 – volume: 31 start-page: 362 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0055 article-title: Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010-11 influenza season publication-title: Vaccine doi: 10.1016/j.vaccine.2012.10.112 – volume: 56 start-page: 1216 year: 2013 ident: 10.1016/j.vaccine.2013.08.097_bib0150 article-title: Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age publication-title: Clin Infect Dis doi: 10.1093/cid/cit045 – volume: 6 start-page: e23049 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0095 article-title: Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women-Taiwan, November 2009–August 2010 publication-title: PLoS One doi: 10.1371/journal.pone.0023049 – volume: l30 start-page: 267 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0135 article-title: AdimFlu-S influenza A (H1N1) vaccine during pregnancy the Taiwanese Pharmacovigilance Survey publication-title: Vaccine – volume: 102 start-page: e33 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0110 article-title: H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes publication-title: Am J Public Health doi: 10.2105/AJPH.2011.300606 – volume: 146 start-page: e1 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0075 article-title: Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990–2009 publication-title: Am J Obstet Gynecol – volume: 29 start-page: 6358 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0105 article-title: Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study publication-title: Vaccine doi: 10.1016/j.vaccine.2011.04.114 – volume: 64 start-page: 252 year: 2001 ident: 10.1016/j.vaccine.2013.08.097_bib0185 article-title: Postmarketing surveillance for human teratogenicity: a model approach publication-title: Teratology doi: 10.1002/tera.1071 – volume: 21 start-page: 844 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0225 article-title: Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models publication-title: Drug Saf – volume: 61 start-page: 113 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0035 article-title: Influenza vaccination coverage among pregnant women-29 states and New York City, 2009–10 season publication-title: MMWR Morb Mortal Wkly Rep – volume: 204 start-page: S107 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0040 article-title: Behaviors and perceptions regarding seasonal and H1N1 influenza vaccination during pregnancy publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2011.02.041 – volume: 30 start-page: 4445 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0125 article-title: A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.081 – volume: 7 start-page: e52303 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0145 article-title: Low rate of pandemic A/H1N1 2009 influenza infection and lack of severe complication of vaccination in pregnant women: a prospective cohort study publication-title: PLoS One doi: 10.1371/journal.pone.0052303 – ident: 10.1016/j.vaccine.2013.08.097_bib0210 – volume: 31 start-page: 213 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0060 article-title: Theory-based predictors of influenza vaccination among pregnant women publication-title: Vaccine doi: 10.1016/j.vaccine.2012.10.064 – volume: 22 start-page: 33 year: 2013 ident: 10.1016/j.vaccine.2013.08.097_bib0200 article-title: Influenza vaccine safety in pregnancy: can we identify exposures publication-title: Drug Saf – volume: 204 start-page: S47 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0015 article-title: Safety of influenza vaccination during pregnancy publication-title: Am J Obstet Gynecol – volume: 9 start-page: 3708 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0100 article-title: Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination publication-title: Vaccine doi: 10.1016/j.vaccine.2011.02.097 – volume: 31 start-page: 2874 year: 2013 ident: 10.1016/j.vaccine.2013.08.097_bib0065 article-title: Barriers to influenza vaccination among pregnant women publication-title: Vaccine doi: 10.1016/j.vaccine.2013.04.031 – volume: 184 start-page: 645 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0085 article-title: Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial publication-title: CMAJ doi: 10.1503/cmaj.110754 – year: 1975 ident: 10.1016/j.vaccine.2013.08.097_bib0235 – volume: 8 start-page: e1000441 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0080 article-title: Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retorspective cohort study publication-title: PLoS Med. doi: 10.1371/journal.pmed.1000441 – volume: 54 start-page: 1 year: 2005 ident: 10.1016/j.vaccine.2013.08.097_bib0025 article-title: Prevention and control of influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm Rep – volume: 116 start-page: 1006 year: 2010 ident: 10.1016/j.vaccine.2013.08.097_bib0030 article-title: ACOG Committee Opinion No. 468: influenza vaccination during pregnancy publication-title: Obstet Gynecol doi: 10.1097/AOG.0b013e3181fae845 – volume: 17 start-page: 156 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0045 article-title: Reasons why women accept or reject the trivalent inactivated influenza vaccine (TIV) during pregnancy publication-title: Matern Child Health J doi: 10.1007/s10995-012-0957-3 – volume: 163 start-page: 1149 year: 2006 ident: 10.1016/j.vaccine.2013.08.097_bib0230 article-title: Variable selection for propensity score models publication-title: Am J Epidemiol doi: 10.1093/aje/kwj149 – volume: 58 start-page: 1 year: 2009 ident: 10.1016/j.vaccine.2013.08.097_bib0070 article-title: Use of influenza A (H1N1) 2009 monovalent vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 publication-title: MMWR Morb Mortal Wkly Rep – volume: 12 start-page: S168 issue: S1 year: 2003 ident: 10.1016/j.vaccine.2013.08.097_bib0195 article-title: The Slone Drug Dictionary: a research driven pharmacoepidemiology tool publication-title: Pharmacoepidemiol Drug Saf – volume: 344 start-page: e2794 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0115 article-title: Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark publication-title: BMJ doi: 10.1136/bmj.e2794 – volume: 29 start-page: 9649 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0140 article-title: Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study publication-title: Vaccine doi: 10.1016/j.vaccine.2011.10.034 – volume: 79 start-page: 65 year: 2007 ident: 10.1016/j.vaccine.2013.08.097_bib0205 article-title: Reporting birth defects surveillance data 1968–2003 publication-title: Birth Defects Res A Clin Mol Teratol – volume: 204 start-page: S3 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0005 article-title: Effects of influenza on pregnant women and infants publication-title: Am J Obstet Gynecol – start-page: S38 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0020 article-title: Safety of influenza immunization during pregnancy for the fetus and the neonate publication-title: Am J Obstet Gyn doi: 10.1016/j.ajog.2012.07.002 – volume: 204 start-page: S64 year: 2011 ident: 10.1016/j.vaccine.2013.08.097_bib0175 article-title: Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2011.01.047 – volume: 32 start-page: 793 year: 1963 ident: 10.1016/j.vaccine.2013.08.097_bib0215 article-title: Intrauterine growth as estimated from liveborn birthweight data at 24 to 42 weeks of gestaton publication-title: Pediatrics doi: 10.1542/peds.32.5.793 – volume: 36 start-page: 455 year: 2013 ident: 10.1016/j.vaccine.2013.08.097_bib0170 article-title: The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza publication-title: Drug Saf doi: 10.1007/s40264-013-0030-1 – year: 2013 ident: 10.1016/j.vaccine.2013.08.097_bib0180 article-title: Risks and safety of H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects publication-title: Vaccine doi: 10.1016/j.vaccine.2013.08.096 – volume: 308 start-page: 165 year: 2012 ident: 10.1016/j.vaccine.2013.08.097_bib0120 article-title: Risk of adverse fetal outcomes following administration of a pandemic influenza A (H1N1) vaccine during pregnancy publication-title: JAMA doi: 10.1001/jama.2012.6131 – volume: 116 start-page: 503 year: 2005 ident: 10.1016/j.vaccine.2013.08.097_bib0190 article-title: Organization of Teratology Information Services Research Group. Asthma medication use in pregnancy and fetal growth publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.05.027 |
| SSID | ssj0005319 |
| Score | 2.3943777 |
| Snippet | •Information is needed on safety of pandemic H1N1 influenza vaccines in pregnancy.•1032 exposed pregnant women were followed to pregnancy outcome,... Highlights•Information is needed on safety of pandemic H1N1 influenza vaccines in pregnancy. •1032 exposed pregnant women were followed to pregnancy outcome,... There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza (pH1N1)-containing... Introduction There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza... Introduction: There is a need for additional information on the fetal risks and relative safety of the pandemic H1N1 monovalent or trivalent influenza... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5026 |
| SubjectTerms | Abortion abortion (animals) Abortion, Spontaneous - epidemiology Adult Allergy and Immunology Applied microbiology Biological and medical sciences Birth defects Canada cohort studies confidence interval congenital abnormalities Congenital Abnormalities - epidemiology Epidemiological Monitoring Exposure Female Fetuses Fundamental and applied biological sciences. Psychology gestational age Humans Immunization Infant, Newborn Infant, Small for Gestational Age Infants influenza Influenza A Virus, H1N1 Subtype Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza, Human - prevention & control Interviews Microbiology Miscellaneous pandemic Pandemic H1N1 influenza vaccination Pandemics Pregnancy Premature Birth - epidemiology Preterm delivery Prospective Studies Risk Risk assessment Safety Small for gestational age Spontaneous abortion Studies Swine flu United States Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Virology women |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgCDQJISgMCmMyEtpTsyWNaye8IEBME9LQBBvqm-X4g3Xr0tBkSOWP4W_lLnESIY2O18QXf-R89zv7Pgh5bTMGVoDhAShrFrDI6iB1QgUis5wJo6yOMRr56DM_PGWfppOpP3ArvVtlKxNrQW0WGs_I90HvJQmg60i8LX4EWDUKb1d9CY3b5A6mLkOXLjEVvYtHXBf2ADMDhxFO-wie_fO9n0rj1TV6d8V1Fk_M-3S9brpfqBJWzDWlLv6NRWuddPCQPPBgkr5r_v4jcsvmA3K3KS-5GpB7R_7ifEB2j5sU1asRPekjrsoR3aXHffJqoBl8Q_-YOkiXtuSPye8vs_KipCo3tFTOViu6cLTA8-fLmaZnUR7RWVPt5JeifsrwhBZL-x0zeqze0PezZXVGja3dR0YUPXMBl9rFFXwW-BD5Y4TtUVVAszn6i8Bo6y4v1XxOAV1TvAzzp5cUBCF2in48T8jpwceTD4eBr-wQaJ6KKtAmszBarnRm3Fg7C3oy1M6lsTVKc24wkSCGvYJ9FQk9SU0kLFPaJZEG5lLxFtnIF7l9Rmg61iCyEgdWfsKUSrModkZxl4VxlsSJGBLW_lOpfdpzrL4xl61_27n06yKRFSRW5UyBbK8jK5q8HzcR8JZhZBvUCmJYgma6iVBcR2hLL0xKGclyLEP5NazBazgF2IERz0CZdJQeLzU46H863fmLp7s5jkUKKjBOh2S7ZXLZD6Tbg0PyqnsN8ggvmRqWAVOSATBCO3hdG84AeSeTdW0mEdiyHDb1mjYcszMCCIuH5GmzEfuJMJh8EqbP10_kBdnEZWncM7fJRrW8si8BZlbZTi1L_gBiIH9J priority: 102 providerName: ProQuest |
| Title | Risks and safety of pandemic h1n1 influenza vaccine in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X13012097 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X13012097 https://dx.doi.org/10.1016/j.vaccine.2013.08.097 https://www.ncbi.nlm.nih.gov/pubmed/24016809 https://www.proquest.com/docview/1558848717 https://www.proquest.com/docview/1443415487 https://www.proquest.com/docview/1464505857 https://www.proquest.com/docview/1516756958 https://www.proquest.com/docview/1686713033 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemIRASQlC-CmMyEtpT0yaNY8e8bdWmAlpVjQ31zXIcm2V0bdV0SOWBP4W_lbt8tEyMDvGStuldY7uX393F90HIW5sw8AJS7oGyZh4LrPGkE9oTieVMpNqaELORjwe8f8Y-jKLRFunVuTAYVllhf4npBVpXZzrVanZmWdb55Be63B8BCmMCKGaUMyZQyts_fgvzCIvmHkjsIfU6i6dz0f6mDW5fY4RXWFTyxNpPN-unBzOdw6q5st3F3-3RQi8dPSIPK4OS7pdjfky27KRB7pYtJpcNcu-42jxvkL1hWaZ62aKn66yrvEX36HBdwBp4Gp8xRqZI1KU1-xPy8yTLv-ZUT1Kaa2cXSzp1dIbPoC8zQ8-DSUCzsuPJd02rKcMZOpvbL1jVY_mOHmTzxTlNbRFC0qIYnQu2qZ1ewc-CLKKMtJAe1QWQjTFmBEZbXPJSj8cULGyKG2LVE0wKYIgXxViep-Ts6PC01_eq7g6e4VIsPJMmFkbLtUlS1zXOgq70jXMytKk2nKdYTBBTX8HHCoSJZBoIy7RxcWBAwHT4jGxPphP7glDZNQBbsQNPP2ZayyQIXaq5S_wwicNYNAmr_1NlqtLn2IFjrOoYtwtVrYtCUVDYmVMCW3vFNitrf9zGwGuBUXViK0CxAu10G6O4idHmFaDkKlB5V_nqD6FvknjFee2--ZeL7l6T6dUcu0KCGgxlk-zUQq7WA4kwtRncbOB_s_oaMAk3mkqRAXeSgXGEvvAmGs7A-o6jTTRRAP4sl1G8gYZjhUYwxMImeV7eiOuJMJh87MuX_79Ir8h9_ITWSiB2yPZifmVfgxm6SHYLnIGjGAk4xj14f2f__cf-AF4PDgfDk18aq45A |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELZGJ14khKC8FcYwEuxTsyWN68RICDHY1LG1qrYO9ZtxHJt1dG1pOlD5MfwEfiN3eWmENDq-7GviS3L25e45-14IeWkiBl5AzB0w1sxhntGOsIFygshwFsTKaB-zkdsd3jpmH_vN_gr5XeTCYFhloRNTRR2PNe6Rb4HdC0NA117wdvLNwa5ReLpatNDIxGLfzH-Ay5a82fsA6_uq0djd6b1vOXlXAUdzEcwcHUdGWcOVjmLb0NaAjna1tcI3sdKcx1jEDlMuAdt7gW6K2AsMU9qGngbGlA_PvUZWmQ-3K2R1e6fTPSyDSvy0lQg4Nsi42y9zhrZON78rjYflGE_mp3VDsdLUxdbw9kQlsEY2a67xb_SbWsHdu-RODl_pu0ze7pEVM6qS61lDy3mV3GjnR_VVstHNimLP67RX5ngldbpBu2W5bKCpfsKInDQtmBbk98mvw0HyNaFqFNME5nE2p2NLJ7jjfTbQ9MQbeXSQ9Vf5qWjOMlyhk6n5gjVE5q_p9mA6O6GxSQNW6hRjgQEJm_E5PBYkHyWyjuPROMGwIUaowNemrzxTwyEFPE_x-C3fL6WgevGlGDn0gBxfyao_JJXReGQeEyoaGpRkaLlwQ6aUiDzfxorbyPWj0A-DGmHFmkqdF1rHfh9DWUTUncp8XiSKgsQ-oALINhdkk6zSyGUEvBAYWaTRguKXYAsvIwwuIjRJrr4S6cmkIV155KZw2e0D0MEca6AMF5Q5QsuQ1_-8dP0vmV7w2AgEGF1f1MhaIeSy_JDFX18jLxa3QQPisVYmMuC8MoBi6HkvG8MZYP2wuWxM0wPvmYtmuGQMx3qQAPv8GnmU_YglIwyYD13xZDkjz8nNVq99IA_2OvtPyS2cIsRCXrBGKrPpuXkGIHcWreeahZLPV63M_gDEzsBL |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbhMxELVKERUSQhBugVKMBH3KNuu92GskhIAStZRWFbRV3ozXa9OUNAnZFBQ-hg_h65jZSyKkkvLS18Szu2OPZ87YcyHkmU0j8AIy7oGxjryIWeNJJ7QnUssjkWlrQsxG3t3jW4fR-27cXSK_61wYDKusdWKhqLOhwTPyNti9JAF0zUTbVWER-5udV6NvHnaQwpvWup1GKSI7dvoD3Lf85fYmrPXzIOi8O3i75VUdBjzDpZh4JkutdpZrk2YuMM6CvvaNczK0mTacZ1jQDtMvAeczYWKZMWEjbVzCDDCpQ3juFXJVhDHDPSa6Yh5eEhZNRcDFwSnwu_PsofbJxndt8NocI8vCooIo1pw63y7eGOkcVsuVbTb-jYMLe9i5RW5WQJa-LiXvNlmygwa5Vra2nDbIym51ad8g6_tleexpix7Ms73yFl2n-_PC2UDTOMLYnCJBmNbkd8ivj738a071IKM5zOJkSoeOjvDs-7Rn6DEbMNorO6381LRiGX6ho7H9gtVEpi_om954ckwzW4SutChGBQMmtsMzeCzsAZTNFo5HMwXD-hirAl9bvPJU9_sUkD3Fi7jq5JSCEsaXYgzRXXJ4KWt-jywPhgP7gFAZGFCXiePSTyKtZcpCl2nuUj9MkzARTRLVa6pMVXIdO3_0VR1bd6KqeVEoCgo7gkog25iRjcqaIxcR8FpgVJ1QCyZAgVW8iFCcR2jzSpHliqk8UL765BfA2e8C5MFsa6BMZpQVVisx2P-8dO0vmZ7xGAgJ5jeUTbJaC7maf8hs_zfJ09nfoAvxgqsUGXBjIwBl6IMvGsMjQP1JvGhMzMCP5jJOFozhWBkSAGDYJPfLjThnJALmE18-XMzIE7ICKkx92N7beUSu4wwhKGJilSxPxmf2MaDdSbpWqBVKPl-2HvsDLlTDGw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risks+and+safety+of+pandemic+h1n1+influenza+vaccine+in+pregnancy%3A+Birth+defects%2C+spontaneous+abortion%2C+preterm+delivery%2C+and+small+for+gestational+age+infants&rft.jtitle=Vaccine&rft.au=Chambers%2C+Christina+D.&rft.au=Johnson%2C+Diana&rft.au=Xu%2C+Ronghui&rft.au=Luo%2C+Yunjun&rft.date=2013-10-17&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.volume=31&rft.issue=44&rft.spage=5026&rft.epage=5032&rft_id=info:doi/10.1016%2Fj.vaccine.2013.08.097&rft.externalDocID=S0264410X13012097 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X13X00477%2Fcov150h.gif |